Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2 1

Status

Completed 154Terminated 31Unknown 24Withdrawn 16Recruiting 11Active not recruiting 10Not yet recruiting 3Suspended 1No longer available 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Leukemia, Myeloid, Acute 5Multiple Myeloma 3Uveal Melanoma 2Melanoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroblastoma 1Neoplasms 1Myelodysplastic Syndromes 1Muscle Neoplasms 1Leukemia, Plasma Cell 1Chronic Pain 1Breast Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Dexamethasone 16daratumumab 14Bortezomib 11Lenalidomide 9pomalidomide 7Calcium Dobesilate 6isatuximab 4belantamab mafodotin 4Cyclophosphamide 4carfilzomib 3Melphalan 3tocilizumab 2iberdomide 2dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Specimen Handling 2Maintenance 2Injections 2Immunotherapy, Adoptive 2Exercise Therapy 2Drug Therapy 2CT103A chimeric antigen receptor 2Biopsy 2zanubrutinib 1trametinib 1talquetamab 1selinexor 1pembrolizumab 1ixazomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × Multiple Myeloma × Melphalan × Clear all
NCT07624513 2026-06-03

Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

Dana-Farber Cancer Institute

Phase 3 Not yet recruiting
720 enrolled
Plasma cell

Multiple Myeloma

NCT07542418 2026-04-21

Study of Thiotepa Combination With Melphalan (TM Protocol) Conditioning for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma:A Prospective Randomized Controlled Clinical Trial

First Affiliated Hospital Xi'an Jiaotong University

Phase NA Not yet recruiting
204 enrolled
Plasma cell

Multiple Myeloma

NCT07029776 2026-03-03

MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma

University of Arkansas

Phase 2 Not yet recruiting
50 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡